Iron and ferritin concentrations in patients with aplastic anemia in relation to EPAG treatment. Longitudinal values of plasma iron (measured by colorimetric assay; reference range, 37-145 µg/dL in females and 59-158 µg/dL in males) and ferritin (measured by immunoassay; reference range, 13-150 µg/L in females and 30-400 µg/L in males) in (A) refSAA patients and (B) MAA patients before, during, and after EPAG treatment. RefSAA patients with iron studies available from baseline and at least one follow-up time point at 3 or 6 months of EPAG treatment were included in the analysis (38 of 40 enrolled patients). Selected MAA patients shown in panel B (n = 19) received no red blood cell transfusions on study (see supplemental Figure 1 for iron studies for the entire MAA study cohort). Posttreatment iron studies were performed at a median 12 months (range, 0.7-25.2 months) after EPAG was discontinued in refSAA patients and 2 months in MAA patients (range, 1.0-7.3 months). P values were calculated on the basis of paired Student t tests. ***P < .001; **P < .01; *P < .05. ns, not significant.